,i #aagth ,,congress #b;d ,session ,h4 ,r4 #gcjh ,,in ,,the ,,house ,,of ,,representatives ,march #ca1 #bjbb,mrs4 ,greene of ,georgia introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to direct the ,inspector ,general of the ,department of ,health and ,human ,services to investigate and report on the ,vaccine ,adverse ,event ,reporting ,system1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,justice for ,vaccine ,victims ,act of #bjbb4 #b4 ,investigation on ,vaccine ,adverse ,event ,reporting ,system 7a7 ,in general ,the ,inspector ,general of the ,department of ,health and ,human ,services shall investigate the ,vaccine ,adverse ,event ,reporting ,system of the ,centers for ,disease ,control and ,prevention and ,food and ,drug ,administration4 7b7 ,required questions 7#a7 ,individuals 7,a7 ,in conducting the investigation under subsection 7a71 the ,inspector ,general of the ,department of ,health and ,human ,services shall ask every individual who reported an adverse event to a ,,covid-#ai vaccine at a minimum the following questions3 7i7 ,which ,,covid-#ai vaccine did you receive8 7ii7 ,which vaccine did you receive as a booster shot8 7iii7 ,do you have any allergies or preexisting conditions8 7iv7 ,was the adverse event mild1 such as minor pain or swelling1 or severe1 such as leading to hospitalization1 disability1 or death8 7v7 ,can you describe in detail the symptoms of the adverse event8 7vi7 ,in detail1 can you describe any health problems you believe were caused by the adverse event8 7vii7 ,are you aware of any other individuals within your community who had a similar adverse event8 7viii7 ,when receiving a vaccination did you notice anything suspicious regarding how the vaccination was administered8 7ix7 ,how soon after the adverse event did you report it to the ,vaccine ,adverse ,event ,reporting ,system8 7x7 ,did you seek compensation for the adverse event through the ,countermeasures ,injury ,compensation ,program8 7xi7 ,would you be willing to testify under oath to a congressional committee8 7,b7 ,if an individual described in subparagraph 7,a7 is deceased1 the ,inspector ,general of the ,department of ,health and ,human ,services shall ask one or more of the individual's immediate family members to answer 7on the individual's behalf7 the questions listed in subparagraph 7,a74 7#b7 ,manufacturers ,in conducting the investigation under subsection 7a71 the ,inspector ,general of the ,department of ,health and ,human ,services shall ask each manufacturer of a ,,covid-#ai vaccine that is distributed in the ,united ,states1 at a minimum1 the following questions and requests3 7,a7 ,what are the ingredients in your ,,covid-#ai vaccine or vaccines distributed in the ,united ,states8 7,b7 ,can you provide all information relating to your manufacturing methods and your data on the stability and safety of the product8 7,c7 ,what is the address of each of your locations involved in the manufacture of the vaccines8 7,d7 ,did you include labeling of the vaccine or vaccines containing a specific statement describing how suspected adverse events can be reported8 7,e7 ,can you provide substantive evidence you have followed all ,food and ,drug ,administration guidance regarding product safety8 7,f7 ,how many adverse events did you report to the ,vaccine ,adverse ,event ,reporting ,system pursuant to section #babe of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;aa-#be7 or other applicable law8 7,g7 ,are you conducting your own internal review of any adverse events caused by the vaccine or vaccines8 7,h7 ,are you ensuring that all public statements regarding vaccine safety are accurate8 7,i7 ,are you limiting reporting data regarding adverse events8 7,j7 ,would you be willing to direct representatives to testify under oath to a congressional committee8 7#c7 ,health care providers ,in conducting the investigation under subsection 7a71 the ,inspector ,general of the ,department of ,health and ,human ,services shall ask a representative sample of health care providers1 at a minimum1 the following questions3 7,a7 ,how many adverse events did you report to the ,vaccine ,adverse ,event ,reporting ,system pursuant to section #babe of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;aa-#be7 or other applicable law8 7,b7 ,what kind of compensation does your facility receive for vaccine administration and from which source or sources8 7,c7 ,is your facility keeping a record of any increase in hospitalization rates for individuals with adverse events following vaccination8 7,d7 ,how many severe adverse events has your facility encountered8 7,e7 ,how many mild adverse events has your facility encountered8 7,f7 ,has your facility determined if adverse events are caused by an immune response to the vaccine8 7,g7 ,is your facility keeping a record of any problems with vaccine administration8 7,h7 ,is your facility keeping a record of all breakthrough cases of ,,covid-#ai in fully vaccinated patients8 7,i7 ,has your facility terminated any health care professionals who are opposed to vaccine mandates or who have raised questions regarding adverse events8 7,j7 ,would you be willing to direct representatives of your facility to testify under oath to a congressional committee8 7c7 ,reports 7#a7 ,report on ,,vaers 7,a7 ,in general ,not later than #c months after the date of enactment of this ,act1 the ,inspector ,general of the ,department of ,health and ,human ,services shall-- 7i7 complete the investigation under subsection 7a72 and 7ii7 publish a report on the results of such investigation4 7,b7 ,contents ,the report under subparagraph 7,a77ii7 shall include the following3 7i7 ,a list of all reported ,,covid-#ai vaccine related deaths and injuries in chronological order4 7ii7 ,transcripts of all interviews conducted by the ,inspector ,general pursuant to this section with an individual described in subsection 7b77#a71 a manufacturer described in subsection 7b77#b71 or a health care provider described in subsection 7b77#c74 7iii7 ,a list of recommendations on how the ,centers for ,disease ,control and ,prevention and the ,food and ,drug ,administration can strengthen the ,vaccine ,adverse ,event ,reporting ,system to be a more reliable method of obtaining information about adverse events4 7iv7 ,a determination on whether the ,centers for ,disease ,control and ,prevention or the ,food and ,drug ,administration is hiding data regarding adverse events4 7v7 ,a determination on whether the ,food and ,drug ,administration is suppressing data on the effectiveness of monoclonal antibodies that are used to treat ,,covid-#ai4 7vi7 ,recommendations on further actions the ,congress can take when conducting oversight regarding data collection by the ,centers for ,disease ,control and ,prevention and the ,food and ,drug ,administration4 7vii7 ,a determination on whether adverse events are common or rare following administration of a ,,covid-#ai vaccine4 7viii7 ,a determination of any causal relationship between any ,,covid-#ai vaccine and specific adverse events using clinical1 laboratory1 or epidemiologic evidence4 7ix7 ,a determination on whether adverse events are intrinsic to the ,,covid-#ai vaccine 7meaning provoked by the immune response caused by the vaccine7 or related to faulty production or administration of the ,,covid-#ai vaccine4 7#b7 ,report on investigation 7,a7 ,in general ,not later than #f months after publishing the report required by paragraph 7#a77;,a77ii71 the ,inspector ,general of the ,department of ,health and ,human ,services shall submit to the relevant congressional committees a report on the implementation of this section4 7,b7 ,contents ,the report under subparagraph 7,a7 shall-- 7i7 specify1 of the amount authorized by subsection 7c77#a7 to be appropriated to carry out this section1 the total amount obligated and expended2 and 7ii7 describe how such amount was used4 7d7 ,subpoena power ,the ,inspector ,general of the ,department of ,health and ,human ,services may1 pursuant to authorities vested in the ,inspector ,general by other applicable law1 issue subpoenas requiring the attendance and testimony of witnesses and the production of any evidence relating to any matter under investigation pursuant to this section4 7e7 ,authorization of appropriations 7#a7 ,in general ,to carry out this section1 there is authorized to be appropriated #ajj1jjj1jjj for the period beginning on the date of enactment of this ,act and ending on the date of submission of the report required by subsection 7b77#b74 7#b7 ,offset 7,a7 ,repeal of deduction for certain ,state and local1 etc41 taxes of individuals ,section #afd7;b77#f7 of the ,internal ,revenue ,code of #aihf is amended by-- 7i7 striking and before ,january #a1 #bjbf-- and all that follows through a separate return74 and inserting paragraphs 7#a71 7#b71 and 7#c7 of subsection 7a7 and paragraph 7#e7 of this subsection shall not apply42 and 7ii7 by striking for taxable years #bjah through #bjbe in the heading thereof4 7,b7 ,effective date ,the amendments made by this paragraph shall apply to taxable years beginning after the date of the enactment of this ,act4 #c4 ,termination of ,,covid-#ai public health emergency declaration under ,public ,readiness and ,emergency ,preparedness 7,,prep7 ,act 7a7 ,in general ,the ,secretary of ,health and ,human ,services shall-- 7#a7 not later than #c months after the date of enactment of this ,act1 terminate the public health emergency declaration issued in connection with ,,covid-#ai pursuant to section #cai;,f-#c of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;d72 and 7#b7 not reissue any such declaration or any substantially similar declaration4 7b7 ,corresponding termination of liability protection ,no immunity from suit and liability under section #cai;,f-#c of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;d7 shall apply with respect to the administration to or the use by an individual of a covered countermeasure if-- 7#a7 the immunity relies on a declaration described in subsection 7a72 and 7#b7 the administration or use occurs after such declaration is terminated1 except that the ,secretary of ,health and ,human ,services1 pursuant to section #cai;,f-#c7;b77#c77;,b7 of such ,act 7#db ,u4,s4,c4 #bdg;d-#f;d7b77#c77;,b771 shall specify an additional immunity period of #c months for the manufacturer to arrange for disposition of the covered countermeasure and for covered persons to take such other actions as may be appropriate to limit administration or use of the covered countermeasure1 as described in clauses 7i7 and 7ii7 of such section #cai;,f-#c7;b77#c77;,b74